---
title: "Goldman Sachs expects Alibaba Health's stock price to experience short-term fluctuations, maintaining a \"Neutral\" rating"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/247432175.md"
description: "Goldman Sachs expects Alibaba Health's stock price to experience short-term fluctuations and maintains a \"Neutral\" rating. Alibaba issued over 12 billion yuan in zero-coupon convertible bonds, with an initial conversion price of 6.23 yuan per share, representing a premium of 37.8% over the previous closing price. If fully converted, it will account for approximately 12% of Alibaba Health's issued share capital. Goldman Sachs believes that Alibaba Health remains an important player in driving the \"AI + Healthcare\" industry transformation within the Alibaba Group ecosystem, with a target price of 4.1 yuan, but prefers JD Health"
datetime: "2025-07-07T03:39:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247432175.md)
  - [en](https://longbridge.com/en/news/247432175.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247432175.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/247432175.md) | [繁體中文](https://longbridge.com/zh-HK/news/247432175.md)


# Goldman Sachs expects Alibaba Health's stock price to experience short-term fluctuations, maintaining a "Neutral" rating

Goldman Sachs published a research report stating that Alibaba (09988.HK)(BABA.US) announced the issuance of over HKD 12 billion zero-coupon convertible bonds (CB), which can be exchanged for shares of ALI HEALTH (00241.HK), with an initial conversion price equivalent to HKD 6.23 per share of ALI HEALTH, representing a premium of 37.8% over its previous closing price. Goldman Sachs estimates that if fully converted, it would amount to 1.926 billion shares of ALI HEALTH, accounting for approximately 12% of its issued share capital. This bond issuance may lead to short-term fluctuations in the stock price of ALI HEALTH, but it will also increase the liquidity of ALI HEALTH shares.

Goldman Sachs indicated that the business cooperation between ALI HEALTH and Alibaba Group remains unchanged, and it continues to be an important player in driving the "AI + healthcare" industry transformation within the group's ecosystem, maintaining its "Neutral" rating with a target price of HKD 4.1. However, based on the current risk-return level, the firm prefers JD Health (06618.HK) over ALI HEALTH

### 相关股票

- [ALI HEALTH (00241.HK)](https://longbridge.com/zh-CN/quote/00241.HK.md)

## 相关资讯与研究

- [Alibaba Chairman Credits Power Grid, Open Source For China's AI Boom](https://longbridge.com/zh-CN/news/280137675.md)
- [Alibaba ties AI push to cloud growth, ecommerce overhaul](https://longbridge.com/zh-CN/news/279986683.md)
- [Strategy declares STRC preferred dividend of $0.96 per share for April](https://longbridge.com/zh-CN/news/281362701.md)
- [Nvidia Stock (NVDA) Braces for a Quick Snapback after a Rare Two-Quarter Losing Streak](https://longbridge.com/zh-CN/news/281360100.md)
- [Nvidia Makes Equity Investment In Marvell Technology, Deepens NVLink Fusion Partnership](https://longbridge.com/zh-CN/news/281388869.md)